Abstract:ObjectiveTo investigate the clinical and genetic characteristics of a case of myelodysplastic syndrome(MDS) secondary to Shwachman-Diamond syndrome(SDS). MethodsThe clinical data of a child with SDS admitted to the Department of Pediatric Hematology, Affiliated Hospital of Jining Medical University on July 31, 2020 were retrospectively analyzed. The clinical and genetic characteristics of children with SDS were summarized, and the literature was reviewed to generalize the progress in diagnosis and treatment for SDS. ResultsThe child was 13 years old and developed steatorrhea 2 months after birth. The child exhibited delayed growth and development in height and weight, with excessive curvature of the fingers. Following child health follow-up and multiple physical examinations, red blood cells, white blood cells, and platelets of blood routine were normal. On December 4, 2019, the patient was treated for fever, and the blood routine showed that red blood cells, white blood cells, and platelets were reduced. Further bone marrow puncture examination showed reduced hyperplasia of granulocytes, red blood cells, and giant cells. Bone marrow immunophenotype showed that the proportion of bone marrow original cells was 2.70%, the expression of CD38 was weakened, and the phenotype was abnormal. The proportion of granulocytes was significantly decreased, mainly composed of mature granulocytes. No abnormal expression was found in erythrocyte, monocyte and lymphocyte. No treatment was given, and subsequent irregular reexamination of blood routine showed that red blood cells, white blood cells, and platelets were reduced. On July 31, 2020, the child was re-admitted due to persistent fever and hemocytopenia, and further genetic testing revealed 2 mutations in the SBDS gene: NM-016038.4: exon2: c.258+2 T>C splice site mutation and NM-016038.4: exon2: c.184 A>T nonsense mutation. Considering the clinical manifestations since birth, the child was definitely diagnosed with SDS. Subsequent bone marrow smear cytology showed that the blast cells accounted for 11.50%. Combined with bone marrow flow cytometry, bone marrow biopsy and immunohistochemistry, secondary MDS were considered, and the TP53 gene mutation rate was 4.10%. On April 11, 2021, the patient underwent a hematopoietic stem cell transplant from an unrelated donor and experienced a short period of remission. However, the patient relapsed 10 months after transplant and eventually died due to total bone marrow recurrence, secondary infection, and bleeding. ConclusionPatients with SDS require close monitoring for bone marrow conditions, and hematopoietic stem cell transplantation should be performed as soon as possible after a definite diagnosis, and TP53 gene mutation indicates poor prognosis.
张滕 陶艳玲 . Shwachman-Diamond综合征继发骨髓增生
异常综合征一例及文献复习[J]. 中华诊断学电子杂志, 2024, 12(3): 178-182.
Zhang Teng,Tao Yanling. A case of secondary myelodysplastic syndrome in a patient with Shwachman-Diamond syndrome and literature review. zhzdx, 2024, 12(3): 178-182.
[1]Farooqui SM, Ward R, Aziz M. Shwachman-Diamond syndrome[EB/OL].(2021-07-25)[2021-09-11].https://www.ncbi.nlm.nih.gov/books/NBK507866/.
[2]谭丽群,傅晓燕,谢晓恬.中国儿童Shwachman-Diamond综合征的表现特征与诊治研究[J].中国当代儿科杂志,2020,22(5):505-511.DOI:10.7499/j.issn.1008-8830.1911111.
[3]Bezzerri V,Cipolli M.Shwachman-Diamond syndrome:molecular mechanisms and current perspectives[J].Mol Diagn Ther,2019,23(2):281-290.DOI:10.1007/s40291-018-0368-2.
[4]Lindsley RC, Saber W, Mar BG, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation[J].N Engl J Med,2017,376(6):536-547.DOI:10.1056/NEJMoa1611604.
[5]Welch JS,Petti AA,Miller CA,et al.TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes[J].N Engl J Med,2016,375(21):2023-2036.DOI:10.1056/NEJMoa1605949.
[6]Kim YJ, Jung SH, Hur EH, et al. TP53 mutation in allogeneic hematopoietic cell transplantation for de novo myelodysplastic syndrome[J].Leuk Res,2018(74):97-104.DOI:10.1016/j.leukres.2018.10.004.
[7]Della Porta MG,Gallì A,Bacigalupo A,et al.Clinical effects of driver somatic mutations on the outcomes of patients with myelodysplastic syndromes treated with allogeneic hematopoietic stem-cell transplantation[J].J Clin Oncol,2016,34(30):3627-3637.DOI:10.1200/JCO.2016.67.3616.
[8]Myers KC,Furutani E,Weller E,et al.Clinical features and out-comes of patients with Shwachman-Diamond syndrome and my-elodysplastic syndrome or acute myeloid leukaemia:a multicentre,retrospective,cohort study[J].Lancet Haematol,2020,7(3):e238-e246.DOI:10.1016/S 2352-3026(19)30206-6.
[9]刘俊丽,史宝海,姚国,等.Shwachman-Diamond综合征1例报告[J].中国实用儿科杂志,2017,32(11):878-880.DOI:10.19538/j.ek2017110618.
[10]Orelio C,van der Sluis RM,Verkuijlen P,et al.Altered intracellular localization and mobility of SBDS protein upon mutation in Shwachman-Diamond syndrome[J].PLoS One,2011,6(6):e20727.DOI:10.1371/journal.pone.0020727.
[11]Normatov I,Sentongo T.Pancreatic malnutrition in children[J].Pediatr Ann,2019,48(11):e441-e447.DOI:10.3928/19382359-20191018-01.
[12]温贤浩,肖剑文,于洁,等.儿童Shwachman-Diamond综合征5例并文献复习[J].中国当代儿科杂志,2013,12(11):970-974.DOI:10.7499/j.issn.1008-8830.2013.11.010.
[13]Shankar RK,Giri N,Lodish MB,et al.Bone mineral density in patients with inherited bone marrow failure syndromes[J].Pediatr Res,2017,82(3):458-464.DOI:10.1038/pr.2017.117.
[14]Dror Y,Donadieu J,Koglmeier J,et al.Draft consensus guidelines for diagnosis and treatment of Shwachman-Diamond syndrome[J].Ann N Y Acad Sci,2011(1242):40-55.DOI:10.1111/j.1749-6632.2011.06349.x.
[15]孙青,谢瑶,吴鹏辉,等.Shwachman-Diamond综合征三例临床诊治和基因分析[J].中国全科医学,2022,25(5):620-624,635.DOI:10.12114/j.issn.1007-9572.2021.01.603.
[16]Boocock GR,Morrison JA,Popovic M,et al.Mutations in SBDS are associated with Shwachman-Diamond syndrome[J].Nat Genet,2003,33(1):97-101.DOI:10.1038/ng1062.
[17]Nelson AS,Myers KC. Diagnosis,treatment,and molecular pathology of shwachman-diamond syndrome[J].Hematol Oncol Clin North Am,2018,32(4):687-700.DOI:10.1016/j.hoc.2018.04.006.
[18]Cesaro S,Pegoraro A,Sainati L,et al.A prospective study of hematologic complications and long-term survival of Italian patients affected by Shwachman-Diamond syndrome[J].J Pediatr,2020(219):196-201.e1.DOI:10.1016/j.jpeds.2019.12.041.
[19]Boocock GR,Morrison JA,Popovic M,et al.Mutations in SBDS are associated with Shwachman-Diamond syndrome[J].Nat Genet,2003,33(1):97-101.DOI:10.1038/ng1062.
[20]Carapito R,Konantz M,Paillard C,et al.Mutations in signal recognition particle SRP54 cause syndromic neutropenia with Shwachman-Diamond-like features[J].J Clin Invest,2017,127(11):4090-4103.DOI:10.1172/JCI92876.
[21]Morini J,Nacci L,Babini G,et al.Whole exome sequencing discloses heterozygous variants in the DNAJC21 and EFL1 genes but not in SRP54 in 6 out of 16 patients with Shwachman-Diamond syndrome carrying biallelic SBDS mutations[J].Br J Haematol,2019,185(3):627-630.DOI:10.1111/bjh.15594.
[22]Kathuria R,Poddar U,Yachha SK.Shwachman-Diamond syndrome:are we missing many?[J].Indian Pediatr,2012,49(9): 748-749.DOI:10.1007/s13312-012-0138-x.
[23]Cesaro S,Pillon M,Sauer M,et al.Long-term outcome after allogeneic hematopoietic stem cell transplantation for Shwachman-Diamond syndrome:a retrospective analysis and a review of the literature by the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation (SAAWP-EBMT)[J].Bone Marrow Transplant,2020,55(9):1796-1809.DOI:10.1038/s41409-020-0863-z.
[24]Burroughs LM,Shimamura A,Talano JA,et al.Allogeneic hematopoietic cell transplantation using treosulfan-based conditioning for treatment of marrow failure disorders[J].Biol Blood Marrow Transplant,2017,23(10):1669-1677.DOI:10.1016/j.bbmt.2017.06.002.